Biocytogen Pharmaceuticals (Beijing) Co Ltd (SHSE:688796) Stock Price, Trades & News

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	2.68
Equity-to-Asset	0.58
Debt-to-Equity	0.27
Debt-to-EBITDA	2.26
Interest Coverage	3.93
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	18.25	Distress Grey Safe
Beneish M-Score	-2.5	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	34.5
	3-Year Book Growth Rate	19.1
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	69.7
	Future 3-5Y Total Revenue Growth Rate Estimate	35.52

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	46.34
	9-Day RSI	51.99
	14-Day RSI	53.95
	3-1 Month Momentum %	-10.53
	6-1 Month Momentum %	28.77

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.31
	Quick Ratio	2.12
	Cash Ratio	1.68
	Days Inventory	147.03
	Days Sales Outstanding	63.91
	Days Payable	128.79

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-3.6
	Shareholder Yield %	-2.59

Profitability Rank

4/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	75.84
	Operating Margin %	20.22
	Net Margin %	12.59
	EBITDA Margin %	18.8
	FCF Margin %	20.48
	OCF Margin %	26.85
	ROE %	13.41
	ROA %	6.08
	ROIC %	13.6
	3-Year ROIIC %	-385.08
	ROC (Joel Greenblatt) %	18.19
	ROCE %	11.72
	Years of Profitability over Past 10-Year	2

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	106.66
	Forward PE Ratio	160.27
	PE Ratio without NRI	108.03
	Price-to-Owner-Earnings	128.37
	PS Ratio	13.33
	PB Ratio	9.31
	Price-to-Tangible-Book	9.36
	Price-to-Free-Cash-Flow	64.93
	Price-to-Operating-Cash-Flow	49.61
	EV-to-EBIT	176.06
	EV-to-EBITDA	176.06
	EV-to-Revenue	33.1
	EV-to-FCF	161.88
	Price-to-GF-Value	2.6
	Price-to-Graham-Number	6.71
	Price-to-Net-Current-Asset-Value	33.82
	Price-to-Net-Cash	1671.43
	Earnings Yield (Greenblatt) %	0.57
	FCF Yield %	0.61

Financials

Annual Quarterly TTM

SHSE:688796's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Biocytogen Pharmaceuticals (Beijing) Co Ltd Executives

Details

GF Value™: ¥45.06

SHSE:688796

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 688796. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ¥)	1,378.808
	EPS (TTM) (¥)	0.43
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	-
	14-Day RSI	53.95
	14-Day ATR (¥)	13.06278
	20-Day SMA (¥)	110.419
	12-1 Month Momentum %	-
	52-Week Range (¥)	48.06 - 154.99
	Shares Outstanding (Mil)	443.48

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Biocytogen Pharmaceuticals (Beijing) Co Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Biocytogen Pharmaceuticals (Beijing) Co Ltd Stock Events

Financials Calendars

	Event	Date	Price (¥)
No Event Data

Biocytogen Pharmaceuticals (Beijing) Co Ltd Frequently Asked Questions

What is Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796)'s stock price today?

The current price of SHSE:688796 is ¥117.00. The 52 week high of SHSE:688796 is ¥154.99 and 52 week low is ¥48.06.

When is next earnings date of Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796)?

The next earnings date of Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796) is .

Does Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796) pay dividends? If so, how much?

Biocytogen Pharmaceuticals (Beijing) Co Ltd(SHSE:688796) does not pay dividend.

Press Release

	Subject	Date
	Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors	2023-12-18

10/Page

Articles on Biocytogen Pharmaceuticals (Beijing) Co Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.